



COEXISTENT GOUT AND SYSTEMIC LUPUS ERYTHEMATOSUS 
ROBERT A. MOIDEL and ARMIN E. GOOD 
We are unaware of any previous report con- 
cerning the coexistence of gout and systemic lupus ery- 
thematosus (SLE). Since gout is a relatively common 
disease affecting over 500,000 Americans (l), it seems 
likely that it would occur in some patients with SLE. In 
fact, on the basis of disease prevalence data (2), approx- 
imately 100 cases of coexistent gout and SLE might be 
expected in the United States (Table 1). This report 
documents the first known case of coexistent gout and 
SLE, and the various factors that may contribute to the 
lack of association between these diseases are discussed. 
Case Report. The patient was a 48-year-old 
white man who was first seen at the Ann Arbor Veter- 
ans Administration Medical Center in November 1979 
with nephrotic syndrome. He had a 10-year history of 
intermittent arthralgia of the ankles, feet, hands, and el- 
bows, a 15-year history of intermittent urticaria, a posi- 
tive LE cell test, and hypocomplementemia. The patient 
had been treated with 5-10 mg prednisone per day for 5 
years. In 1978 he developed hypertension, 10-pound 
weight gain, and proteinuria. The serum uric acid was 
13 mg/100 ml. He was placed on diuretics and contin- 
ued on low dose prednisone, but by 1979 severe periph- 
eral edema and fatigue developed. The patient denied a 
history of Raynaud's phenomenon, mucosal ulcerations, 
alopecia, and photosensitivity. 
The physical examination was remarkable for a 
blood pressure of 215/105 and 4+ pitting edema up to 
the knees. Laboratory data included hemoglobin 1 1.3 
gm/ 100 ml, hematocrit 3 1.7%, white blood count 5,300, 
platelets 220,000, BUN 25 mg/100 ml, creatinine 1.9 
mg/100 ml, uric acid 11 mg/100 ml, creatinine clear- 
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ance 70 ml/minute, 18 gm/proteinuria per 24 hours, 
microscopic hematuria, antinuclear antibody positive at 
1 :40 with a homogeneous pattern, DNA binding 81.5% 
(normal up to 25%), total hemolytic complement 
(CH50) 87 (normal 104-188), C3 79 (normal 85-191), 
and normal C4. Radiographs of the hands and ankles 
were unremarkable. Results of renal biopsy disclosed 
severe mixed diffuse proliferative and membranous glo- 
merulonephritis with subepithelial and subendothelial 
deposits and myxovirus-like bodies on electron micros- 
COPY * 
The patient was placed on prednisone 60 mg/ 
day, propranolol 80 mg/day, furosemide 320 mg/day, 
and hydralazine 100 mg/day. Over the next 6 months, 
the prednisone was tapered to 20 mg/day. During that 
time, he began to complain of intermittent mild meta- 
tarsalgia. In June 1980, the patient developed tender- 
ness, warmth, swelling, and erythema over the right first 
metatarsophalangeal (MTP) joint and metatarsal bone. 
Passive flexion and extension of the first MTP joint 
were painless. His temperature was 38.1"C and white 
blood count was 6,500, and a presumptive diagnosis of 
cellulitis was given. The patient was placed on intra- 
venous nafcillin for the next four days. His right foot 
improved somewhat, but subsequently the left first 
MTP joint and metatarsal area became similarly erythe- 
matous, painful, and swollen. The serum uric acid was 
10.8 mg/100 ml, and the CH50, C3, C4, and DNA 
binding were normal. An x-ray of the right foot re- 
vealed an erosion with overhanging margins at the head 
of the first metatarsal bone and another erosion at the 
second MTP joint (Figure 1). Aspiration of synovial 
fluid from the left first MTP joint yielded white blood 
cells filled with negatively birefringent needle-shaped 
crystals consistent with monosodium urate. Nafcillin 
was stopped, indomethacin was begun, and the inflam- 
mation in the feet resolved over the next several days. 
Discussion. This patient had a well established 
diagnosis of SLE manifesting as biopsy proven neph- 
ritis, arthralgias, and urticaria, and characterized by the 
presence of elevated DNA binding values and hypo- 
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Table 1. Expected concurrence of gout and systemic lupus 



















52,500 X 0.10% 52 
482,500 X 0.01 1% 53 
I05 
complementemia when the disease was active. Proof 
that he had gout occurred on finding crystals of uric 
acid in the joint aspiration. That he did not have con- 
comitant infection was proved by the rapid resolution of 
the pain and swelling on indomethacin alone. 
A search through the medical literature reveals 
that there are no other reports of coexistent gout and 
SLE. The age and sex disparity between the two dis- 
eases and the rarity of SLE itself are probably the major 
reasons for the negative association. In addition, the 
lack of such cases may be due in part to possible under- 
diagnosis of gout in lupus patients. Gout may not be 
suspected in a patient whose arthritis is attributed to es- 
tablished SLE. 
Alterations in the complement system may be an 
additional important factor that inhibits the develop- 
ment of gout in the milieu of SLE. It has been demon- 
strated that the complement system may play an in- 
tegral role in the pathogenesis of gouty arthritis. 
Incubating sodium urate crystals in human serum acti- 
vates the complement cascade, evidenced by a con- 
sumptive depletion of complement components includ- 
ing C3 (3). Some patients have decreased C3 levels in 
the synovial fluid of the involved joint during an acute 
attack (4). Complement also enhances phagocytosis of 
sodium urate crystals and generates chemotactic activ- 
ity, both of which help mediate the acute inflammatory 
response in gout (5) .  Animals depleted of complement 
exhibit diminished urate-induced inflammation (6). 
Thus, there is evidence that synovial fluid complement 
may be an important mediator of urate-induced inflam- 
mation, and a characteristic of patients with SLE is a 
marked decrease in synovial complement levels, even 
when the serum C3 level is normal (4). If urate crystals 
require near normal levels of synovial complement to 
induce inflammation, then the presence of decreased 
complement levels in SLE may pose a bamer to urate- 
Figure 1. Erosion at the head of the right first metatarsophalangeal 
joint. 
induced inflammation and make the coexistence of gout 
and SLE very unlikely. 
The negative association between gout and rheu- 
matoid arthritis (1,7-11) may similarly involve the re- 
duced synovial fluid complement levels found in rheu- 
matoid arthritis (4), inhibiting the expression of clinical 
gout. 
In conclusion, the rarity of the association of 
gout and SLE may be due to the disparity of the popu- 
lations that each disease affects, the rarity of SLE itself, 
and the clinical difficulty in distinguishing an acute 
gouty attack from a flare of lupus arthritis rather than 
any true pathogenetic incompatibility between the two 
diseases. Conversely, the presence of low synovial fluid 
complement levels in SLE and rheumatoid arthritis may 
present an important blockade for the development of 
gouty arthritis since the presence of synovial fluid com- 
plement seems to be required for mediation of this in- 
flammatory process. Further studies of the mechanism 
of urate-induced inflammation may clarify the reasons 
for the disassociation between gouty arthritis and SLE. 
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ADDENDUM 
Since acceptance of this manuscript for pub- 
lication, we have discovered another case of coexistent 
BRIEF REPORTS 97 I 
gout and SLE. The patient is a 39-year-old woman with 
SLE and membranous nephropathy since 1966 who de- 
veloped tophaceous gout in 1976. The gout is presently 
controlled with allopurinol, and she has been on main- 
tenance hemodialysis for several months. At the onset 
of gout, her creatinine was 1.4 mg/100 ml and the uric 
acid was 12 mg/100 ml 
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